SageView Advisory Group LLC Increases Stake in Merck & Co., Inc. (NYSE:MRK)

SageView Advisory Group LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 94.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,032 shares of the company’s stock after acquiring an additional 16,983 shares during the quarter. SageView Advisory Group LLC’s holdings in Merck & Co., Inc. were worth $3,819,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $3,108,366,000. Wellington Management Group LLP raised its stake in Merck & Co., Inc. by 6.7% in the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock worth $8,487,472,000 after buying an additional 5,196,914 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock valued at $3,966,029,000 after purchasing an additional 4,731,152 shares during the period. Bank of Nova Scotia grew its position in shares of Merck & Co., Inc. by 352.2% in the 4th quarter. Bank of Nova Scotia now owns 3,144,632 shares of the company’s stock worth $342,814,000 after buying an additional 2,449,211 shares during the period. Finally, Public Employees Retirement Association of Colorado increased its stake in shares of Merck & Co., Inc. by 29,914.1% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 2,410,732 shares of the company’s stock valued at $262,818,000 after purchasing an additional 2,402,700 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on MRK shares. Truist Financial upped their price objective on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Merck & Co., Inc. in a research note on Tuesday, June 4th. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price on the stock. in a research note on Monday, March 11th. Berenberg Bank upped their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Finally, Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Get Our Latest Research Report on MRK

Merck & Co., Inc. Price Performance

Shares of NYSE MRK traded up $0.05 during midday trading on Friday, reaching $129.42. 1,627,935 shares of the stock traded hands, compared to its average volume of 7,982,192. The company’s 50 day moving average is $128.59 and its 200 day moving average is $122.14. Merck & Co., Inc. has a one year low of $99.14 and a one year high of $133.10. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The stock has a market capitalization of $327.80 billion, a PE ratio of 143.66, a P/E/G ratio of 2.51 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. During the same quarter last year, the business earned $1.40 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts anticipate that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Monday, June 17th. This represents a $3.08 annualized dividend and a yield of 2.38%. Merck & Co., Inc.’s payout ratio is currently 342.22%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.